WHY
TYVASO
FOR PH-ILD
SO you can offer
your patients hope2,3
TYVASO and TYVASO DPI are inhaled prostacyclin mimetics indicated for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.3,4
The study with TYVASO establishing effectiveness predominately included patients with etiologies of 3,4:
- Idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF)
- Combined pulmonary fibrosis and emphysema (CPFE) (25%)
- WHO Group 3 connective tissue disease (22%)
WHY TYVASO?
UNITED THERAPEUTICS CARES™ CO-PAY ASSISTANCE PROGRAM
AS LITTLE AS
$0
| PER CO-PAY
United Therapeutics offers a Co-Pay Assistance Program for eligible patients.
Get in contact with a United Therapeutics Representative
REQUEST A REPDPI=dry powder inhaler; WHO=World Health Organization.
The information contained in this section of the site is clinical in nature and specifically created for healthcare professionals. If you are not a US healthcare professional, please click CLOSE to return to the consumer section of the site.